139 related articles for article (PubMed ID: 29650809)
1. [Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Shimodaira H
Gan To Kagaku Ryoho; 2018 Apr; 45(4):587-592. PubMed ID: 29650809
[TBL] [Abstract][Full Text] [Related]
2. [Specific features of drug sensitivity of hereditary cancers].
Imyanitov EN
Vopr Onkol; 2016; 62(2):221-6. PubMed ID: 30452211
[TBL] [Abstract][Full Text] [Related]
3. Personalized Systemic Therapies in Hereditary Cancer Syndromes.
Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
[TBL] [Abstract][Full Text] [Related]
4. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
5. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
6. Genetic testing by cancer site: ovary.
Weissman SM; Weiss SM; Newlin AC
Cancer J; 2012; 18(4):320-7. PubMed ID: 22846732
[TBL] [Abstract][Full Text] [Related]
7. Leveraging DNA repair deficiency in gynecologic oncology.
Walsh CS; Hodeib M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
[TBL] [Abstract][Full Text] [Related]
8. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
9. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory PARP w terapii raka jajnika.
Kruczała MA; Grela-Wojewoda A; Cedrych I
Ginekol Pol; 2016; 87(2):131-4. PubMed ID: 27306290
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing for cancer predisposition.
Eng C; Hampel H; de la Chapelle A
Annu Rev Med; 2001; 52():371-400. PubMed ID: 11160785
[TBL] [Abstract][Full Text] [Related]
12. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.
Tafe LJ
J Mol Diagn; 2015 Sep; 17(5):472-82. PubMed ID: 26162329
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
16. Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience.
Foretova L; Petrakova K; Palacova M; Kalabova R; Svoboda M; Navratilova M; Schneiderova M; Bolcak K; Krejci E; Drazan L; Mikova M; Hazova J; Vasickova P; Machackova E
Klin Onkol; 2010; 23(6):388-400. PubMed ID: 21348412
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Colicchia V; Petroni M; Guarguaglini G; Sardina F; Sahún-Roncero M; Carbonari M; Ricci B; Heil C; Capalbo C; Belardinilli F; Coppa A; Peruzzi G; Screpanti I; Lavia P; Gulino A; Giannini G
Oncogene; 2017 Aug; 36(33):4682-4691. PubMed ID: 28394338
[TBL] [Abstract][Full Text] [Related]
18. Clinical genetics of hereditary colorectal cancer.
Power DG; Gloglowski E; Lipkin SM
Hematol Oncol Clin North Am; 2010 Oct; 24(5):837-59. PubMed ID: 20816577
[TBL] [Abstract][Full Text] [Related]
19. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
Wang Z; Qian H; Yiu SM; Sun J; Zhu G
J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
[TBL] [Abstract][Full Text] [Related]
20. Advances in the recognition and management of hereditary cancer.
Kulkarni A; Carley H
Br Med Bull; 2016 Dec; 120(1):123-138. PubMed ID: 27941041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
